Background Salicylic acid (SA) is present in the serum of people who have not taken salicylate drugs. Now we have examined the urine of these subjects and found that it contains SA and salicyluric acid (SU). We have established the identities of these phenolic acids and determined their concentrations.
Introduction
Extracts of certain plants have been used for centuries to treat in£ammatory conditions, and it has been established that the salicylates present in these extracts are the anti-in£ammatory agents. 1 Aspirin (acetylsalicylic acid) is used to treat cardiovascular disease, and it is widely taken by many people for its analgesic, antipyretic and anti-in£ammatory actions. After administration, aspirin undergoes rapid hydrolysis to generate salicylic acid (SA), and it is this phenolic acid that may be responsible for the persistence of the anti-in£ammatory e¡ect of aspirin. 2 Paterson et al., 3 using high-performance liquid chromatography (HPLC), gas chromatography^mass spectrometry (GCMS) and salicylate hydroxylase, demonstrated that SA and two of its hydroxylated metabolites were present in the serum of people who had not taken salicylate drugs, and they suggested that these phenolic acids may have had a dietary origin. Swain et al. 4 determined SA in foodstu¡s using HPLC with UV detection and estimated that the dietary intake of SA was in the range 70^1100 mol per person per 24 h. Janssen et al. 5 examined acid-treated urine using HPLC with £uorescence detection, and suggested that the dietary intake of SA was about 10 mol per person per 24 h. However, neither Swain et al. nor Janssen et al. had characterized the compound(s) they had determined. Moreover, because both groups had used treatments with acid, it is possible that other salicylates, salicylate precursors and structurally related compounds had been determined and had been included in the values they reported.
SA, produced after the administration of aspirin, has a half-life of 2^4 h in blood 6 and, as might be expected under these conditions, concentrations of salicylate in urine, at least in the form of its major urinary metabolite salicyluric acid (SU) (2-hydroxybenzoylglycine), are considerably higher than those in serum. 7 Therefore, we examined the urine of people who have not taken salicylate drugs to see if it contained SA and SU and to determine their concentrations if present.
Urine
Urine excreted over a 24-h period was obtained from 10 volunteers (six female, four male, median age 32¢4 years, range 16^53 years) who had not taken salicylate drugs during the 2-week period prior to donating the urine. The volume of urine excreted was measured and creatinine concentration was measured on a Beckman CX3 analyser. Aliquots were stored at ¡208C prior to analysis. All investigations were approved by the local research ethics committee and informed consent was obtained.
Instrumentation
Chromatographic mobile phases were degassed using a Jour X Act 4 channel degasser (Presearch) and applied to a Prodigy ODS 3 m column (Phenomenex, Mac-cles¢eld, UK) via a PU80 pump and an LG980 Ternary Gradient Unit (Jasco, Great Dunmow, UK). The substances eluted were detected using an Antec Decade.
The electrochemical detector (Presearch) was adjusted to an oxidation potential of ‡ 1¢1V. The substances extracted from urine were fractionated by HPLC and speci¢c eluates collected. These were then esteri¢ed and separated by gas chromatography on a DB-5 capillary column (30 m£0¢25 mm) ¢tted to a Fisons 8000 series gas chromatograph interfaced with an MD 800 mass spectrometer (Thermoquest, Manchester, UK).
Extraction of salicylates from urine
After thawing, 0¢5 mL aliquots of urine to which had been added internal standard (4-methylsalicylic acid; ¢nal concentration 10 mol/L) and tripotassium EDTA (¢nal concentration 100 mol/L) were adjusted to pH 2 using 1mol/L HCl. Two mL of ethyl acetate were added and the mixtures were vortexed for 15 min. After centrifuging at 2000g for 10 min at 48C, the upper organic phases of the mixtures were removed and the aqueous layers re-extracted with 2 mL of ethyl acetate. The combined extracts were dried at 708C with a stream of N 2 and the residues were dissolved in 0¢5 mL of 100 mol/L EDTA. Prior to drying, the glassware had been rinsed with doubledistilled water and then with single -distilled acetone. Salicylates were not detected in the HPLC -grade water.
HPLC
Volumes of 50 L of aqueous solutions of authentic SA, SU and the reconstituted extracts of urine were applied to the column. Citrate bu¡er [30 mmol/ L trisodium citrate containing 50% methanol (v/v) and brought to pH 4¢0 with acetic acid] was used as mobile phase A; citrate bu¡er (30 mmol/ L trisodium citrate brought to pH 3 ¢ 8 with acetic acid) was used as mobile phase B in a programme of stepwise and gradient elution (see Table 1 ). The column temperature was maintained at 308C.
GCMS
A 5 mL aliquot of urine (subsequently found to contain 0¢84 mol/L SA and 5¢56 mol/L SU) was extracted with ethyl acetate as previously described and the dried extract was dissolved in HPLC mobile phase B (0¢5 mL). Fifty microlitres of the reconstituted extract was applied to the HPLC column and elution was performed according to the programme described in Table 1 . The electrochemical detector was switched o¡ in order to prevent oxidation of the eluted substances. The fraction eluting between 1 min prior to the R t of SU and 1min after the R t of SA was extracted with 2 mL of ethyl acetate. SA (200 g), SU (200 g) and the dried extract were treated with 2 mL of acetyl chloride in methanol (300 L of acetyl chloride added to 10 mL of methanol containing 0¢1% water). The mixtures were heated at 608C for 4 h and then dried at 608C with a stream of N 2 . The residues were dissolved in 2 mL of ethyl acetate and volumes of 1 L were applied to the GC column. The temperature of the column was increased from 548C at 118C/min until it reached 3008C. The injection port temperature was 2008C. The mass spectrometer electron energy was ‡ 70 eV set in full scan mode.
Calibration
Calibration graphs, of the ratio of the detector response due to the determinand to that due to 4-methylsalicylic acid against determinand concen- tration, were constructed for both SA and SU using aqueous solutions of SA and SU (concentration range 0¢02^20¢0 mol/L). These plots were linear and passed through the origin.
Precision of the method for determining SA and SU
Intra-assay precision was determined by measuring the concentrations of SA and SU in urine on eight occasions within a 24-h period. Inter-assay precision was determined by measuring the concentration of SA and SU in another specimen of urine on eight occasions within a period of 10 days (a separate extract of the urine was prepared on each occasion).
Results

HPLC of urine extracts
Two of the acidic hydrophobic compounds extracted from the urine of people who had not taken salicylate drugs had retention times that were very similar to those of authentic SA (21¢7 min) and SU (15¢8 min) ( Fig. 1 ). When conditions of elution were changed, by increasing the concentration of methanol in mobile phase A to 65%, the R t of authentic SA and SU were decreased to 16 ¢ 8 min and 10 ¢ 2 min, respectively, and those of two of the hydrophobic compounds were decreased also to values close to these (16¢9 min and 10¢5 min, respectively).
GCMS of HPLC eluates
When authentic SA and SU were esteri¢ed (see Materials and methods) and then analysed by GCMS, the spectra of the esteri¢ed compounds best ¢tted the spectra of methyl salicylate and methyl salicylurate that were present in our spectral library (P£eger, Mauer and Weber). The two hydrophobic compounds isolated from urine with Rts similar to those of salicylic acid and salicyluric acid had, after esteri¢cation, mass spectra that most closely ¢tted (¢rst hits) those of methyl salicylate and methyl salicylurate ( Fig. 2 for principal ion mass spectra).
Assay performance
The intra-assay precisions for the determination of urinary SA (mean concentration 0¢84 mol/L) and SU (mean concentration 5¢56 mol/L) were 0¢58% and 0¢07%, respectively (coe¤cient of variation, CV); nˆ8). The inter-assay precisions for the determination of urinary SA (mean concentration 0¢82 mol/L) and SU (mean concentration 5 ¢ 34 mol/L) were 2¢48% and 2¢43% (CV), respectively (nˆ8). The limit of detection (de¢ned as a signal with an amplitude three times the average baseline noise 8 ) of the method was 50 ¢01 mol/L for the determination of SA and SU. SA and SU were stable in urine stored for 24 h at room temperature, 48C, or at ¡208C.
Analysis of volunteers' urine
When urine collected over 24 h from 10 individuals was examined, both SA and SU were detected in all samples ( Table 2 ). The median value of the ratio of the concentration of SA to that of creatinine was 0¢043 mol/mmol (range 0¢006^0¢276 mol/mmol), and that of SU to creatinine was 0¢47 mol/mmol (range 0¢019^1¢1 mol/mmol).
Discussion
Our results show that SA and SU are components of the urine of people who do not take salicylate drugs. Chromatographic evidence suggested initially that two of the unknown acidic hydrophobic compounds extracted from urine were SA and SU. The chromatographic characteristics of the two unknown compounds were similar to those of SA and SU, and when the conditions of elution were altered the retention times of SA and SU were altered also, and were matched by those of the two unidenti¢ed compounds. Esteri¢cation of the unknown compounds generated derivatives that had gas chromatographic R t very similar to those of the methyl esters of SA and SU. The characteristics of the total ion chromatograms of these compounds showed clearly that they are the methyl esters of SA and SU. Thus, we have established conclusively that SA and SU are present in the urine of subjects who do not take salicylate drugs. Armstrong et al. 9 detected a compound with paper chromatographic characteristics similar to those of SU in the urines of 400 people who had not taken salicylate drugs. Following extraction of acidic hydrophobic compounds into ethyl acetate, these workers recorded the chromatographic behaviour of 49 of these compounds. They suggested that a considerable number of them might have a dietary origin. Von Studnitz and colleagues, 10 also using paper chromatography, studied the excretion in urine of compounds thought to be phenolic acids, by human subjects whose diet was restricted to a solution of glucose and citric acid. They suggested that SA might be one of these compounds. Young 11 reported the presence of a compound with the thin-layer chromatographic characteristics of SU in the urine of a single individual who had consumed a synthetic diet. Finnie and co-workers 12 reported the presence of a compound with the paper chromatographic characteristics of SU in the urine of children who su¡ered from a variety of gastrointestinal conditions and who had not been taking salicylate drugs. At the time of these earlier investiga- tions, 10^12 methods for characterizing and determining the concentrations of SA and SU in urine were not routinely available, and the identities of these compounds were not established. Janssen et al. 5 13 and it is likely that di¡erences in the diet, metabolism and renal function of the subjects may contribute to the width of these ranges. Relatively low concentrations of salicylates, especially SA in the concentration range 0¢1^10 mol/L, may have signi¢cant anti-in£ammatory e¡ects in vivo by inhibiting transcription of cyclooxygenase-2, an enzyme that catalyses the formation of prostaglandins during in-£ammation. 14, 15 Thus analytical methods are required to enable researchers to study the metabolism and excretion of salicylates at these low concentrations, which are found even in people who have not taken salicylate drugs (see also reference 3). This report describes a suitable analytical method. Now we have shown conclusively that SA and SU are components of urine from people who do not take salicylate drugs, and their concentrations indicate that they are derived from SA at concentrations in vivo which may have physiological e¡ects. The CV for the determination of SA and SU in urine by the method we have developed are indicative of acceptable precision, and our method should allow investigations of the origin, metabolism and potential biological signi¢cance of these salicylates without having to resort to invasive procedures (such as obtaining blood). Additionally, measurements of the variation with time of urinary concentrations of salicylates in people who do not take salicylate drugs may provide valuable information regarding the extent of their exposure to salicylates.
